Kyowa Kirin, engages in the manufacture and sale of medical products and pharmaceuticals in the therapeutic areas of nephrology, oncology, and immunology in Japan. Its pharmaceutical products include GRAN, a protein that enables a quick recovery from neutropenia and reduces the risk of infection; NESP, an agent for correcting anemia; ESPO, a glycoprotein, which acts as an anemia-relieving treatment for dialysis patients; and CONIEL, a calcium antagonist agent for hypertension and angina pectoris. The company's pharmaceutical products also comprise REGPARA an agent for the treatment of secondary hyperparathyroidism; ALLELOCK/Patanol, which are used as medicine for patients with various types of allergies; and DEPAKENE/TOPINA, antiepileptic agents. It also offers a range of products, including amino acids, nucleic acids, vitamins, and sugars, which are used to produce pharmaceuticals, health foods, foods, cosmetics, and other products; plant growth regulators, feed additives, companion animal-related products, and aquaculture medicinal products; and various types of alcohol for use in alcoholic beverages. In addition, the company manufactures and sells industrial alcohols and solvents for automotive, electronics, and housing industries; performance materials that enable the production of raw materials for lubricants, higher alcohols, and polymeric materials used in various consumer goods; and a range of electronic materials for the information technology industry. Further, it provides seasonings, sweeteners, freeze-dried products, and bakery products and ingredients. The company was founded in 1885 and is headquartered in Tokyo, Japan. Kyowa Hakko Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.